ClinicalTrials.gg
CompletedNCT04294810SKYSCRAPER-01Updated Nov 9, 2026Results posted

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

A Phase 3 interventional study of Atezolizumab and Tiragolumab in Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 132 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know · 9 judgments · one reading being read again

Updated Nov 9, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. Tiragolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 12
620 · median 74
Started
2020
with 2 others
Phase 3
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
6 of 12
Hoffmann-La Roche

Among the 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 3 that started in 2020, is one of 3 in phase 3, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tiragolumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tiragolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1
  • or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue expression
  • per , Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion criteria

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for (HIV)
  • Active or
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, , anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
620 participants (actual)

Study arms

  • Experimental
    Tiragolumab + Atezolizumab

    Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Tiragolumab

  • Placebo comparator
    Placebo + Atezolizumab

    Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Matching Placebo

Interventions

  • Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

    Also known as: MTIG7192A

  • DrugMatching Placebo

    Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)

    PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

    Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

  2. China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS

    PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

    Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

  3. Global Cohort: Overall Survival (OS) in the PAS

    OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

    Time frame: From randomization to death from any cause (up to approximately 54.7 months)

  4. China Cohort: OS in the PAS

    OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

    Time frame: From randomization to death from any cause (up to approximately 49.1 months)

  5. Global Cohort: Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 65.1 months

  6. China Cohort: Number of Participants With AEs

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to 49.3 months

  7. Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale

    CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

    Time frame: Up to 65.1 months

  8. China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale

    CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

    Time frame: Up to 49.3 months

Secondary outcomes

  1. Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)

    PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

    Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

  2. China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS

    PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

    Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

  3. Global Cohort: OS in the SAS

    OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

    Time frame: From randomization to death from any cause (up to approximately 54.7 months)

  4. China Cohort: OS in the SAS

    OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

    Time frame: From randomization to death from any cause (up to approximately 49.1 months)

  5. Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS

    Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

    Time frame: Up to approximately 54.6 months

  6. China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS

    Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

    Time frame: Up to 49.3 months

  7. Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS

    DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

    Time frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

  8. China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS

    DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

    Time frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

  9. Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS

    PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

    Time frame: At Months 6 and 12

  10. China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS

    PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

    Time frame: At Months 6 and 12

  11. Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS

    PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

    Time frame: At Months 6 and 12

  12. China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS

    PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

    Time frame: At Months 6 and 12

  13. Global Cohort: OS Rate at 12 Months and 24 Months in the PAS

    OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

    Time frame: At Months 12 and 24

  14. China Cohort: OS Rate at 12 Months and 24 Months in the PAS

    OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

    Time frame: At Months 12 and 24

  15. Global Cohort: OS Rate at 12 Months and 24 Months in the SAS

    OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

    Time frame: At Months 12 and 24

  16. China Cohort: OS Rate at 12 Months and 24 Months in the SAS

    OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

    Time frame: At Months 12 and 24

  17. Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS

    TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

    Time frame: Up to approximately 54.6 months

  18. China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS

    TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

    Time frame: Up to approximately 49.3 months

  19. Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS

    TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

    Time frame: Up to approximately 54.6 months

  20. China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS

    TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

    Time frame: Up to approximately 49.3 months

  21. Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)

  22. China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)

  23. Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)

  24. China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)

  25. Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 54.6 months

  26. China Cohort: Number of Participants With ADAs to Tiragolumab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 49.3 months

  27. Global Cohort: Number of Participants With ADAs to Atezolizumab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 54.6 months

  28. China Cohort: Number of Participants With ADAs to Atezolizumab

    Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

    Time frame: Up to approximately 49.3 months

07

Results

Posted Nov 9, 2026

Participant flow

A total of 620 participants with previously untreated locally advanced, unresectable or metastatic programmed death-ligand 1 (PD-L1)-selected non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation took part in the Global \& China extension cohorts of the study at 141 investigative sites across 23 countries from 03 March 2020 to 30 December 2025.

Participant flow — Overall Study
MilestoneGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort Only: Placebo + AtezolizumabChina Cohort Only: Tiragolumab + Atezolizumab
Started2682664145
Global cohort26826600
China cohort004852
Completed0000
Not completed2682664145
Withdrew: Symptomatic deterioration0100
Withdrew: Physician decision1000
Withdrew: Death1711701921
Withdrew: Study ended by sponsor74731921
Withdrew: Withdrawal by subject202122
Withdrew: Lost to follow-up2101
Withdrew: Reason not specified0010

Outcome measures

SecondaryGlobal Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

Time frame:
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
Reported as:
Median · months
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)5.91 (4.99 to 7.26)8.25 (6.44 to 12.22)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.0340 · Hazard ratio (hr): 0.76 · 95% CI 0.60 to 0.98
SecondaryChina Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

Time frame:
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Reported as:
Median · months
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS8.25 (6.24 to 15.24)7.82 (5.09 to 15.70)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Hazard ratio (hr): 1.01 · 95% CI 0.60 to 1.69
SecondaryGlobal Cohort: OS in the SAS

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

Time frame:
From randomization to death from any cause (up to approximately 54.7 months)
Reported as:
Median · months
Global Cohort: OS in the SAS
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: OS in the SAS20.57 (16.59 to 29.34)24.64 (17.87 to 31.97)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.5474 · Hazard ratio (hr): 0.93 · 95% CI 0.73 to 1.18
SecondaryChina Cohort: OS in the SAS

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

Time frame:
From randomization to death from any cause (up to approximately 49.1 months)
Reported as:
Median · months
China Cohort: OS in the SAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: OS in the SASNA (29.27 to NA)NA (21.91 to NA)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Hazard ratio (hr): 1.32 · 95% CI 0.65 to 2.66
SecondaryGlobal Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Time frame:
Up to approximately 54.6 months
Reported as:
Number · percentage of participants
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
percentage of participantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS35.1 (29.39 to 41.33)45.8 (39.69 to 52.04)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Cochran-Mantel-Haenszel · p = 0.0114 · Difference in overall response rates: 10.67 · 95% CI 1.97 to 19.15
SecondaryChina Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions \& normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Time frame:
Up to 49.3 months
Reported as:
Number · percentage of participants
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
percentage of participantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS47.9 (33.52 to 62.64)48.1 (34.22 to 62.22)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Cochran-Mantel-Haenszel · p = 0.9790 · Difference in overall response rates: 0.16 · 95% CI -20.06 to 20.34
SecondaryGlobal Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

Time frame:
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
Reported as:
Median · months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS14.6 (9.7 to 18.6)18.0 (13.6 to 24.4)
SecondaryChina Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target \& non-target lesions \& normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

Time frame:
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Reported as:
Median · months
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS13.9 (9.4 to NA)18.0 (11.8 to 25.8)
SecondaryGlobal Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
percentage of participantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Month 647.84 (41.67 to 54.01)54.62 (48.50 to 60.74)
Month 1224.86 (18.78 to 30.94)37.27 (30.62 to 43.92)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.1265 · Difference in event-free rate: 6.78 · 95% CI -1.91 to 15.47
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.0069 · Difference in event-free rate: 12.41 · 95% CI 3.40 to 21.42
SecondaryChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
percentage of participantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
Month 663.17 (49.24 to 77.10)58.82 (45.32 to 72.33)
Month 1237.03 (23.07 to 50.99)42.26 (28.50 to 56.01)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -4.35 · 95% CI -23.75 to 15.05
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: 5.23 · 95% CI -14.37 to 24.82
SecondaryGlobal Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
percentage of participantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Month 649.54 (42.66 to 56.42)57.42 (50.66 to 64.18)
Month 1227.06 (19.95 to 34.17)42.60 (35.15 to 50.06)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.1090 · Difference in event-free rate: 7.88 · 95% CI -1.76 to 17.53
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.0031 · Difference in event-free rate: 15.54 · 95% CI 5.24 to 25.84
SecondaryChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
percentage of participantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
Month 666.83 (52.61 to 81.05)58.33 (44.39 to 72.28)
Month 1240.58 (25.72 to 55.43)42.83 (28.62 to 57.05)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -8.50 · 95% CI -28.41 to 11.42
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: 2.26 · 95% CI -18.30 to 22.82
SecondaryGlobal Cohort: OS Rate at 12 Months and 24 Months in the PAS

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

Time frame:
At Months 12 and 24
Reported as:
Number · percentage of participants
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
percentage of participantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Month 1262.62 (56.66 to 68.58)67.28 (61.53 to 73.03)
Month 2441.93 (35.80 to 48.05)47.66 (41.49 to 53.82)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.2698 · Difference in event-free rate: 4.66 · 95% CI -3.62 to 12.94
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.1963 · Difference in event-free rate: 5.73 · 95% CI -2.96 to 14.42
SecondaryChina Cohort: OS Rate at 12 Months and 24 Months in the PAS

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

Time frame:
At Months 12 and 24
Reported as:
Number · percentage of participants
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
percentage of participantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
Month 1287.02 (77.32 to 96.72)77.84 (66.26 to 89.42)
Month 2462.49 (47.68 to 77.29)59.40 (44.79 to 74.01)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -9.18 · 95% CI -24.29 to 5.92
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -3.09 · 95% CI -23.89 to 17.71
SecondaryGlobal Cohort: OS Rate at 12 Months and 24 Months in the SAS

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

Time frame:
At Months 12 and 24
Reported as:
Number · percentage of participants
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
percentage of participantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Month 1267.60 (61.21 to 73.98)68.19 (61.85 to 74.54)
Month 2446.27 (39.42 to 53.12)50.29 (43.42 to 57.15)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.8971 · Difference in event-free rate: 0.59 · 95% CI -8.41 to 9.60
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Z-test · p = 0.4173 · Difference in event-free rate: 4.01 · 95% CI -5.69 to 13.72
SecondaryChina Cohort: OS Rate at 12 Months and 24 Months in the SAS

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

Time frame:
At Months 12 and 24
Reported as:
Number · percentage of participants
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
percentage of participantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
Month 1292.97 (85.29 to 100.00)78.55 (66.73 to 90.36)
Month 2468.56 (53.57 to 83.55)61.01 (45.90 to 76.12)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -14.42 · 95% CI -28.51 to -0.33
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Difference in event-free rate: -7.55 · 95% CI -28.83 to 13.74
SecondaryGlobal Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Time frame:
Up to approximately 54.6 months
Reported as:
Median · months
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS16.46 (11.10 to 33.28)16.53 (13.83 to 28.91)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.5659 · Hazard ratio (hr): 0.92 · 95% CI 0.71 to 1.21
SecondaryChina Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Time frame:
Up to approximately 49.3 months
Reported as:
Median · months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PASNA (14.95 to NA)NA (18.43 to NA)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.7271 · Hazard ratio (hr): 0.87 · 95% CI 0.41 to 1.85
SecondaryGlobal Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Time frame:
Up to approximately 54.6 months
Reported as:
Median · months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS15.54 (11.70 to 32.26)22.77 (15.28 to 37.72)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.2052 · Hazard ratio (hr): 0.83 · 95% CI 0.63 to 1.11
SecondaryChina Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Time frame:
Up to approximately 49.3 months
Reported as:
Median · months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PASNA (13.54 to NA)NA (NA to NA)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.9995 · Hazard ratio (hr): 1.00 · 95% CI 0.49 to 2.06
SecondaryGlobal Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
micrograms per milliliter (µg/mL)Global Cohort: Tiragolumab + Atezolizumab
Pre-dose on Day 1 of Cycle 1NA ± NA
30 Minutes EOI on Day 1 of Cycle 1217 ± 35.2
Pre-dose on Day 1 of Cycle 222.3 ± 242.4
Pre-dose on Day 1 of Cycle 343.2 ± 69.2
Pre-dose on Day 1 of Cycle 457.3 ± 62.2
Pre-dose on Day 1 of Cycle 866.7 ± 81.5
Pre-dose on Day 1 of Cycle 1272.4 ± 138.8
Pre-dose on Day 1 of Cycle 1671.3 ± 139.4
TD Visit21.5 ± 541.6
SecondaryChina Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Reported as:
Geometric mean · µg/mL
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
µg/mLChina Cohort: Tiragolumab + Atezolizumab
Pre-dose on Day 1 of Cycle 1NA ± NA
30 Minutes Post-EOI on Day 1 of Cycle 1199 ± 26.4
Pre-dose on Day 1 of Cycle 226.4 ± 49.8
Pre-dose on Day 1 of Cycle 340.3 ± 71.1
Pre-dose on Day 1 of Cycle 440.7 ± 305.5
Pre-dose on Day 1 of Cycle 864.9 ± 42.6
Pre-dose on Day 1 of Cycle 1263.4 ± 28.0
Pre-dose on Day 1 of Cycle 1659.1 ± 77.4
TD Visit38.5 ± 130.0
SecondaryGlobal Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Reported as:
Geometric mean · µg/mL
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
µg/mLGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Pre-dose on Day 1 of Cycle 1NA ± NANA ± NA
30 Minutes Post-EOI on Day 1 of Cycle 1414 ± 29.1427 ± 27.7
Pre-dose on Day 1 of Cycle 268.3 ± 54.764.2 ± 130.6
Pre-dose on Day 1 of Cycle 399.9 ± 125.3112 ± 58.1
Pre-dose on Day 1 of Cycle 4123 ± 115.7139 ± 64.4
Pre-dose on Day 1 of Cycle 8170 ± 106.8180 ± 47.8
Pre-dose on Day 1 of Cycle 12209 ± 45.0190 ± 89.0
Pre-dose on Day 1 of Cycle 16215 ± 42.2206 ± 47.1
TD Visit91.9 ± 221.261.5 ± 346.5
SecondaryChina Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Reported as:
Geometric mean · µg/mL
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
µg/mLChina Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Pre-dose on Day 1 of Cycle 1NA ± NANA ± NA
30 Minutes Post-EOI on Day 1 of Cycle 1467 ± 16.5466 ± 18.5
Pre-dose on Day 1 of Cycle 268.8 ± 69.174.9 ± 35.5
Pre-dose on Day 1 of Cycle 3105 ± 71.2115 ± 55.0
Pre-dose on Day 1 of Cycle 4127 ± 55.8144 ± 34.0
Pre-dose on Day 1 of Cycle 8157 ± 48.0175 ± 32.9
Pre-dose on Day 1 of Cycle 12169 ± 69.9176 ± 28.9
Pre-dose on Day 1 of Cycle 16190 ± 34.4187 ± 57.5
TD Visit100 ± 87.4123 ± 72.8
SecondaryGlobal Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 54.6 months
Reported as:
Count of participants · Participants
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
ParticipantsGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab5
SecondaryChina Cohort: Number of Participants With ADAs to Tiragolumab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 49.3 months
Reported as:
Count of participants · Participants
China Cohort: Number of Participants With ADAs to Tiragolumab
ParticipantsChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Number of Participants With ADAs to Tiragolumab1
SecondaryGlobal Cohort: Number of Participants With ADAs to Atezolizumab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 54.6 months
Reported as:
Count of participants · Participants
Global Cohort: Number of Participants With ADAs to Atezolizumab
ParticipantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Number of Participants With ADAs to Atezolizumab6263
SecondaryChina Cohort: Number of Participants With ADAs to Atezolizumab

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Time frame:
Up to approximately 49.3 months
Reported as:
Count of participants · Participants
China Cohort: Number of Participants With ADAs to Atezolizumab
ParticipantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Number of Participants With ADAs to Atezolizumab1625
PrimaryGlobal Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

Time frame:
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
Reported as:
Median · months
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)5.55 (4.37 to 7.03)7.00 (5.62 to 9.79)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.0226 · Hazard ratio (hr): 0.78 · 95% CI 0.63 to 0.97
PrimaryChina Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

Time frame:
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Reported as:
Median · months
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS7.16 (5.68 to 13.17)7.82 (5.09 to 15.15)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Hazard ratio (hr): 0.94 · 95% CI 0.58 to 1.51
PrimaryGlobal Cohort: Overall Survival (OS) in the PAS

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

Time frame:
From randomization to death from any cause (up to approximately 54.7 months)
Reported as:
Median · months
Global Cohort: Overall Survival (OS) in the PAS
monthsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Overall Survival (OS) in the PAS16.85 (14.59 to 21.32)23.13 (17.71 to 28.78)
Statistical analysis
  • Global Cohort: Placebo + Atezolizumab vs Global Cohort: Tiragolumab + Atezolizumab · Log Rank · p = 0.2165 · Hazard ratio (hr): 0.87 · 95% CI 0.71 to 1.08
PrimaryChina Cohort: OS in the PAS

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

Time frame:
From randomization to death from any cause (up to approximately 49.1 months)
Reported as:
Median · months
China Cohort: OS in the PAS
monthsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: OS in the PAS29.67 (21.88 to NA)28.29 (15.70 to NA)
Statistical analysis
  • China Cohort: Placebo + Atezolizumab vs China Cohort: Tiragolumab + Atezolizumab · Hazard ratio (hr): 1.13 · 95% CI 0.60 to 2.14
PrimaryGlobal Cohort: Number of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Global Cohort: Number of Participants With Adverse Events (AEs)
ParticipantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Number of Participants With Adverse Events (AEs)241256
PrimaryChina Cohort: Number of Participants With AEs

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
China Cohort: Number of Participants With AEs
ParticipantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Number of Participants With AEs4851
PrimaryGlobal Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
ParticipantsGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + Atezolizumab
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale02
PrimaryChina Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, \& end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
ParticipantsChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale00

Adverse events

Collected over Global cohort: Up to 65.1 months; China Cohort: 49.3 months. As pre-specified in SAP, participants enrolled from China during the global enrollment phase were included in the analysis for the China cohort, hence, 15 participants from Global cohorts were included in China cohorts for all analysis.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Global Cohort: Placebo + Atezolizumab179/263 (68.1%)108/263 (41.1%)217/263 (82.5%)
Global Cohort: Tiragolumab + Atezolizumab175/267 (65.5%)117/267 (43.8%)239/267 (89.5%)
China Cohort: Placebo + Atezolizumab21/48 (43.8%)12/48 (25%)47/48 (97.9%)
China Cohort: Tiragolumab + Atezolizumab24/52 (46.2%)20/52 (38.5%)48/52 (92.3%)
Most frequent serious events
Showing 10 of 197
Most frequent serious events
EventGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
PneumoniaInfections and infestations14/26313/2673/487/52
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/2630/2670/483/52
COVID-19Infections and infestations12/2636/2670/480/52
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders0/2630/2671/482/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/2633/2670/480/52
DeathGeneral disorders2/2637/2670/480/52
PneumonitisRespiratory, thoracic and mediastinal disorders6/2636/2671/480/52
Retinal artery occlusionEye disorders1/2630/2671/480/52
PainGeneral disorders1/2630/2671/480/52
PyrexiaGeneral disorders5/2633/2671/481/52
Most frequent other events
Showing 10 of 66
Most frequent other events
EventGlobal Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort: Placebo + AtezolizumabChina Cohort: Tiragolumab + Atezolizumab
AnaemiaBlood and lymphatic system disorders41/26341/26715/4823/52
Aspartate aminotransferase increasedInvestigations28/26329/2678/4816/52
PruritusSkin and subcutaneous tissue disorders47/26379/2678/4816/52
Alanine aminotransferase increasedInvestigations28/26337/2677/4815/52
RashSkin and subcutaneous tissue disorders35/26367/2678/4814/52
HyperglycaemiaMetabolism and nutrition disorders11/26317/26712/487/52
COVID-19Infections and infestations27/26333/2677/4812/52
CoughRespiratory, thoracic and mediastinal disorders28/26341/26711/485/52
HypoalbuminaemiaMetabolism and nutrition disorders7/2637/2679/4810/52
Decreased appetiteMetabolism and nutrition disorders32/26351/2679/486/52

Baseline characteristics

Full analysis set (FAS) included all randomized participants, regardless of whether participants received the assigned treatment.

Age, Customized
Age, Customized(Participants)Global Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort Only: Placebo + AtezolizumabChina Cohort Only : Tiragolumab + AtezolizumabTotal
< 65 years1201111818267
≥ 65 years1481552327353
Sex: Female, Male
Sex: Female, Male(Participants)Global Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort Only: Placebo + AtezolizumabChina Cohort Only : Tiragolumab + AtezolizumabTotal
Female726477150
Male1962023438470
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Global Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort Only: Placebo + AtezolizumabChina Cohort Only : Tiragolumab + AtezolizumabTotal
Hispanic or Latino21110032
Not Hispanic or Latino2442544043581
Unknown or Not Reported31127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Global Cohort: Placebo + AtezolizumabGlobal Cohort: Tiragolumab + AtezolizumabChina Cohort Only: Placebo + AtezolizumabChina Cohort Only : Tiragolumab + AtezolizumabTotal
American Indian or Alaska Native53008
Asian73724145231
Native Hawaiian or Other Pacific Islander00000
Black or African American22004
White18418500369
More than one race12003
Unknown or Not Reported32005
08

Study locations

132 sites
  • Rocky Mountain Cancer Center - Denver
    Denver, Colorado 80220, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • SCRI Florida Cancer Specialists North
    St. Petersburg, Florida 33705, United States
  • SCRI Florida Cancer Specialists PAN
    Tallahassee, Florida 32308, United States
  • US oncology research at Minnesota Oncology
    Saint Paul, Minnesota 55102, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialists (Fairfax) - USOR
    Fairfax, Virginia 22031, United States
  • Onc & Hem Assoc SW Virginia
    Salem, Virginia 24153, United States
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Austin Hospital Olivia Newton John Cancer Centre
    Heidelberg, Victoria 3084, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Klinik Penzing
    Vienna, 1140, Austria
  • Krankenhaus Nord - Klinik Floridsdorf
    Vienna, 1210, Austria
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital de Cancer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Chongqing Cancer Hospital
    Chongqing, 400030, China
  • Fujian Cancer Hospital
    Fuzhou, 350014, China
  • Hainan General Hospital
    Haikou, 570311, China
  • Sir Run Run Shaw Hospital Zhejiang University
    Hangzhou, 310016, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Jinan Central Hospital
    Jinan, 250013, China
  • Meizhou People's Hospital
    Meizhou, 514031, China
  • The 1st Affiliated Hospital of Nanchang Unversity
    Nanchang, 330200, China
  • Nantong Tumor Hospital
    Nantong, 226361, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200120, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, 430022, China
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, 710061, China
  • Zhejiang Cancer Hospital
    Zhejiang, 310022, China
  • Krankenhaus Nordwest
    Frankfurt, 60488, Germany
  • LungenClinic Großhansdorf GmbH
    Großhansdorf, 22927, Germany
  • Krankenhaus Martha-Maria Halle-Doelau gGmbH
    Halle, 06120, Germany
  • Fachklinik für Lungenerkrankungen
    Immenhausen, 34376, Germany
  • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
    Löwenstein, 74245, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie
    Münster, 48153, Germany
  • Klinik Schillerhöhe
    Stuttgart, 70376, Germany
  • Sotiria Hospital
    Athens, 104 31, Greece
  • Metropolitan Hospital
    Athens, 185 47, Greece
  • University Hospital of Larissa
    Larissa, 411 10, Greece
  • Diavalkaniko Hospital
    Thessaloniki, 570 01, Greece
  • Orszagos Koranyi TBC es Pulmonologiai Intezet
    Budapest, 1121, Hungary
  • Matrai Gyogyintezet
    Mátraháza, 3233, Hungary
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
    Szolnok, 5004, Hungary
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    Naples, Campania 80131, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Rome, Lazio 00151, Italy
  • Policlinico Universitario "Agostino Gemelli"
    Rome, Lazio 00168, Italy
  • Irccs Istituto Europeo di Oncologia (IEO)
    Milan, Lombardy 20141, Italy
  • Asst Di Monza
    Monza, Lombardy 20900, Italy
  • Istituto Clinico Humanitas
    Rozzano, Lombardy 20089, Italy
  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    Orbassano, Piedmont 10043, Italy
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    Perugia, Umbria 06156, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS
    Padova, Veneto 35128, Italy
  • Aichi Cancer Center
    Aichi, 464-8681, Japan
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Sendai Kousei Hospital
    Miyagi, 980-0873, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • Saitama Cancer Center
    Saitama, 362-0806, Japan
  • NHO Kinki-Chuo Chest Medical Center
    Sakaishi, 591-8555, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
  • Cryptex Investigacion Clinica SA de CV
    México, Mexico CITY (federal District) 06100, Mexico
  • AVIX Investigación Clínica S.C
    Monterrey, Nuevo León 64710, Mexico
  • Cuidados oncologicos
    Querétaro City, Querétaro 76000, Mexico
  • Jeroen Bosch Ziekenhuis
    's-Hertogenbosch, 5223 GZ, Netherlands
  • Ziekenhuis Gelderse Vallei
    Ede, 6716 RP, Netherlands
  • Frisius MC Leeuwarden
    Leeuwarden, 8934 AD, Netherlands
  • Hagaziekenhuis, locatie Leyweg
    The Hague, 2545 AA, Netherlands
  • Instituto Regional de Enfermedades Neoplásicas del Sur
    Arequipa, 5154, Peru
  • Instituto Nacional de Enfermedades Neoplasicas
    Lima, 15038, Peru
  • Clinica Internacional, Sede San Borja
    Lima, Lima 41, Peru
  • Clinica Ricardo Palma
    San Isidro, Lima 27, Peru
  • Uniwersyteckie Centrum Kliniczne
    Gda?sk, 80-214, Poland
  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
    Olsztyn, 10-357, Poland
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
    Poznan, 60-569, Poland
  • Main Military Clinical Hospital named after N.N. Burdenko
    Moscow, Moscow Oblast 105229, Russia
  • MEDSI Clinical Hospital on Pyatnitsky Highway
    Moscow, Moscow Oblast 143422, Russia
  • Institute of Oncology
    Saint Petersburg, Sankt-Peterburg 189646, Russia
  • Leningrad Regional Clinical Hospital
    Saint Petersburg, Sankt-Peterburg 194291, Russia
  • St. Petersburg Med Univ
    Saint Petersburg, Sankt-Peterburg 197089, Russia
  • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • University Hospital Medical Center Bezanijska kosa
    Belgrade, 11080, Serbia
  • Chungbuk National University Hospital
    Cheongju-si, 28644, South Korea
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, South Korea
  • Ajou University Medical Center
    Gyeonggi-do, 16499, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Chonnam National University Hwasun Hospital
    Jeollanam-do, 58128, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Kangbuk Samsung Medical Center
    Seoul, 03181, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea

Showing the first 100 of 132 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon BJ, Gumus M, Erman M, Bondarenko I, Kim DW, Felip E, Morabito A, Bryl M, Urban L, Nosaki K, Reck M, Meng R, Stroud C, Kundu P, Wen X, Patil NS, Huang M, Troutman S, Matheny C, Cho BC. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Sep;44(25):2400-2408. doi: 10.1200/JCO-25-02777. Epub 2026 Jul 27. PubMed 42507968 ↗
  • Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026 Sep 10;44(26):2507-2516. doi: 10.1200/JCO-26-00327. Epub 2026 Jul 27. PubMed 42507965 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Dec 2025, 69 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 69 months is above that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 4, 2020
StartActual
Mar 4, 2020
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Sites
6 sites added, 8 sites removed
Show 6 added (2 Netherlands, 1 China, 1 Germany, 1 Greece, 1 Russia)
  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • Fachklinik für Lungenerkrankungen · Immenhausen, Germany
  • Diavalkaniko Hospital · Thessaloniki, Greece
  • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
  • Frisius MC Leeuwarden · Leeuwarden, Netherlands
  • Leningrad Regional Clinical Hospital · Saint Petersburg, Russia
Show 8 removed
  • Northwest Cancer Specialists - Vancouver · Vancouver, United States
  • The First Affiliated Hospital of Xiamen University · Xiamen, China
  • Azienda Ospedaliera San Giuseppe Moscati · Avellino, Italy
  • Health Pharma Professional Research · CD Mexico, Mexico
  • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
  • Hospital General Universitario de Alicante · Alicante, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • City Clinical Hospital #4 · Dnipropetrovsk, Ukraine
Nov 9, 2026
Primary outcomes
3 edited, 5 added, 1 removed
What changed in the outcomes
  • EditedGlobal Cohort: Investigator-Assessedassessed Progression-Freefree Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
  • EditedGlobal Cohort: Overall Survival (OS) in the Primary Analysis SetPASTime frame: From randomization to death from any cause (up to approximately 59 months) → From randomization to death from any cause (up to approximately 54.7 months)
  • EditedPercentageGlobal Cohort: Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 59 months → Up to 65.1 months
  • AddedChina Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
  • AddedChina Cohort: OS in the PASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
  • AddedChina Cohort: Number of Participants With AEsTime frame: Up to 49.3 months
  • AddedGlobal Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading ScaleTime frame: Up to 65.1 months
  • AddedChina Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading ScaleTime frame: Up to 49.3 months
  • RemovedPercentage of Participants With Cytokine-Release Syndrome (CRS)Time frame: Up to approximately 59 months
Nov 9, 2026
Documents
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 42507968 ↗
Nov 9, 2026
Secondary outcomes
7 edited, 21 added
What changed in the outcomes
  • EditedGlobal Cohort: Investigator-Assessedassessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
  • EditedGlobal Cohort: OS in the Secondary Analysis SetSASTime frame: From randomization to death from any cause (up to approximately 59 months) → From randomization to death from any cause (up to approximately 54.7 months)
  • EditedGlobal Cohort: Investigator-Assessedassessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PASTime frame: From randomization up to approximately 59 months → Up to approximately 54.6 months
  • EditedGlobal Cohort: Investigator-Assessedassessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PASTime frame: From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
  • EditedGlobal Cohort: Investigator-Assessedassessed PFS RatesRate at 6 Months and 12 Months in the PASTime frame: 6 months, 12 months → At Months 6 and 12
  • EditedGlobal Cohort: OS RatesRate at 12 Months and 24 Months in the PASTime frame: 12 months, 24 months → At Months 12 and 24
  • EditedGlobal Cohort: Time to Confirmed Deterioration (TTCD) Assessed Usingin Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Scorein the PASTime frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 59 months) → Up to approximately 54.6 months
  • AddedChina Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
  • AddedChina Cohort: OS in the SASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
  • AddedChina Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PASTime frame: Up to 49.3 months
  • AddedChina Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PASTime frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
  • AddedChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PASTime frame: At Months 6 and 12
  • AddedGlobal Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SASTime frame: At Months 6 and 12
  • AddedChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SASTime frame: At Months 6 and 12
  • AddedChina Cohort: OS Rate at 12 Months and 24 Months in the PASTime frame: At Months 12 and 24
  • AddedGlobal Cohort: OS Rate at 12 Months and 24 Months in the SASTime frame: At Months 12 and 24
  • AddedChina Cohort: OS Rate at 12 Months and 24 Months in the SASTime frame: At Months 12 and 24
  • AddedChina Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 49.3 months
  • AddedGlobal Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 54.6 months
  • AddedChina Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 49.3 months
  • AddedGlobal Cohort: Serum Concentration of Tiragolumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
  • AddedChina Cohort: Serum Concentration of Tiragolumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
  • AddedGlobal Cohort: Serum Concentration of Atezolizumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
  • AddedChina Cohort: Serum Concentration of Atezolizumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
  • AddedGlobal Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to TiragolumabTime frame: Up to approximately 54.6 months
  • AddedChina Cohort: Number of Participants With ADAs to TiragolumabTime frame: Up to approximately 49.3 months
  • AddedGlobal Cohort: Number of Participants With ADAs to AtezolizumabTime frame: Up to approximately 54.6 months
  • AddedChina Cohort: Number of Participants With ADAs to AtezolizumabTime frame: Up to approximately 49.3 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 42507968 ↗
    6 sites added, 8 sites removed
    Show 6 added (2 Netherlands, 1 China, 1 Germany, 1 Greece, 1 Russia)
    • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • Fachklinik für Lungenerkrankungen · Immenhausen, Germany
    • Diavalkaniko Hospital · Thessaloniki, Greece
    • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
    • Frisius MC Leeuwarden · Leeuwarden, Netherlands
    • Leningrad Regional Clinical Hospital · Saint Petersburg, Russia
    Show 8 removed
    • Northwest Cancer Specialists - Vancouver · Vancouver, United States
    • The First Affiliated Hospital of Xiamen University · Xiamen, China
    • Azienda Ospedaliera San Giuseppe Moscati · Avellino, Italy
    • Health Pharma Professional Research · CD Mexico, Mexico
    • Medisch Centrum Leeuwarden · Leeuwarden, Netherlands
    • Hospital General Universitario de Alicante · Alicante, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • City Clinical Hospital #4 · Dnipropetrovsk, Ukraine
    Primary outcomes 3 edited, 5 added, 1 removed
    What changed in the outcomes
    • EditedGlobal Cohort: Investigator-Assessedassessed Progression-Freefree Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
    • EditedGlobal Cohort: Overall Survival (OS) in the Primary Analysis SetPASTime frame: From randomization to death from any cause (up to approximately 59 months) → From randomization to death from any cause (up to approximately 54.7 months)
    • EditedPercentageGlobal Cohort: Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 59 months → Up to 65.1 months
    • AddedChina Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
    • AddedChina Cohort: OS in the PASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
    • AddedChina Cohort: Number of Participants With AEsTime frame: Up to 49.3 months
    • AddedGlobal Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading ScaleTime frame: Up to 65.1 months
    • AddedChina Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading ScaleTime frame: Up to 49.3 months
    • RemovedPercentage of Participants With Cytokine-Release Syndrome (CRS)Time frame: Up to approximately 59 months
    Secondary outcomes 7 edited, 21 added
    What changed in the outcomes
    • EditedGlobal Cohort: Investigator-Assessedassessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
    • EditedGlobal Cohort: OS in the Secondary Analysis SetSASTime frame: From randomization to death from any cause (up to approximately 59 months) → From randomization to death from any cause (up to approximately 54.7 months)
    • EditedGlobal Cohort: Investigator-Assessedassessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PASTime frame: From randomization up to approximately 59 months → Up to approximately 54.6 months
    • EditedGlobal Cohort: Investigator-Assessedassessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PASTime frame: From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 59 months) → From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
    • EditedGlobal Cohort: Investigator-Assessedassessed PFS RatesRate at 6 Months and 12 Months in the PASTime frame: 6 months, 12 months → At Months 6 and 12
    • EditedGlobal Cohort: OS RatesRate at 12 Months and 24 Months in the PASTime frame: 12 months, 24 months → At Months 12 and 24
    • EditedGlobal Cohort: Time to Confirmed Deterioration (TTCD) Assessed Usingin Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Scorein the PASTime frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 59 months) → Up to approximately 54.6 months
    • AddedChina Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
    • AddedChina Cohort: OS in the SASTime frame: From randomization to death from any cause (up to approximately 49.1 months)
    • AddedChina Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PASTime frame: Up to 49.3 months
    • AddedChina Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PASTime frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
    • AddedChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PASTime frame: At Months 6 and 12
    • AddedGlobal Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SASTime frame: At Months 6 and 12
    • AddedChina Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SASTime frame: At Months 6 and 12
    • AddedChina Cohort: OS Rate at 12 Months and 24 Months in the PASTime frame: At Months 12 and 24
    • AddedGlobal Cohort: OS Rate at 12 Months and 24 Months in the SASTime frame: At Months 12 and 24
    • AddedChina Cohort: OS Rate at 12 Months and 24 Months in the SASTime frame: At Months 12 and 24
    • AddedChina Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 49.3 months
    • AddedGlobal Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 54.6 months
    • AddedChina Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PASTime frame: Up to approximately 49.3 months
    • AddedGlobal Cohort: Serum Concentration of Tiragolumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
    • AddedChina Cohort: Serum Concentration of Tiragolumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
    • AddedGlobal Cohort: Serum Concentration of Atezolizumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
    • AddedChina Cohort: Serum Concentration of Atezolizumab at Specified TimepointsTime frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
    • AddedGlobal Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to TiragolumabTime frame: Up to approximately 54.6 months
    • AddedChina Cohort: Number of Participants With ADAs to TiragolumabTime frame: Up to approximately 49.3 months
    • AddedGlobal Cohort: Number of Participants With ADAs to AtezolizumabTime frame: Up to approximately 54.6 months
    • AddedChina Cohort: Number of Participants With ADAs to AtezolizumabTime frame: Up to approximately 49.3 months
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04294810
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Mar 4, 2020
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

Clinical Trial
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tiragolumab

Start the discussion